Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease by Baldeiras, I et al.
RESEARCH Open Access
Erlangen Score as a tool to predict
progression from mild cognitive
impairment to dementia in Alzheimer’s
disease
Inês Baldeiras1,2,3, Isabel Santana1,2,3, Maria João Leitão2, Daniela Vieira1, Diana Duro1, Barbara Mroczko4,
Johannes Kornhuber5 and Piotr Lewczuk4,5*
Abstract
Background: The previously described and validated Erlangen Score (ES) algorithm enables interpretation of the
cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), ordering them on an ordinal scale: from
neurochemically normal (ES = 0) through improbable AD (ES = 1), possible AD (ES = 2 or 3), to probable AD (ES = 4).
Here we assess the accuracy of the ES in predicting hazards of progression from the mild cognitive impairment (MCI)
stage of AD to the dementia stage of the disease (Alzheimer’s disease dementia (ADD)) in a novel, single-center cohort.
Methods: Baseline CSF biomarkers (amyloid beta (Aβ) 1–42, Aβ42/40, Tau, and pTau181), interpreted according to the
ES, were used to estimate time to progression from the MCI stage of AD to ADD, conditional on age, gender, APOE ε4
genotype, and Mini Mental State Examination score in 144 MCI subjects, using the Extended Cox Model; the subjects
were followed-up until they developed dementia or until they had been cognitively stable for at least 2 years. In
addition, ES distributions were studied in 168 ADD cases and 66 neurologic controls.
Further, we stratified MCI patients into those who progressed to ADD faster (within 3 years, n = 47) and those who
progressed slower (n = 74).
Results: The distributions of the ES categories across the four diagnostic groups (Controls, MCI-Stable, MCI-AD, and
ADD) were highly significantly different (Kruskal–Wallis χ2(df = 3) = 151.4, p < 0.001), with significant contrasts between
each pair (p < 0.005), except between the ADD and the MCI-AD groups (p = 1.0). MCI patients with ES = 2 or 3 had 6–8
times higher hazards to progress to ADD compared to patients with ES = 0 or 1 in the first 3 follow-up years, and then
their hazards decreased to those of the group with ES = 0 or 1. Patients with ES = 4 had hazards 8–12 times higher
compared to the ES = 0 or 1 group. Faster progressors with ES = 2 or 3 had, in comparison to slower progressors,
significantly lower Aβ1–42, Aβ1–40, and Aβ42/40, but comparable Tau and pTau181. A highly significant difference of
the ES distributions between these two groups was observed (p < 0.001).
Conclusions: Our current results reconfirm and extend the conclusions of the previously published report that the
Erlangen Score is a useful tool facilitating interpretation of a complex pattern of the CSF AD biomarkers.
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Background
Decreased concentration of amyloid beta (Aβ) 1–42 pep-
tide, decreased Aβ42/40 ratio, and increased Tau and
pTau181 concentrations in cerebrospinal fluid (CSF)
form the biomarker profile in Alzheimer’s disease (AD)
[1]. This pattern reflects the two pathophysiologic pro-
cesses of the disease: amyloidosis and neurodegenera-
tion. Although the CSF biomarkers demonstrate very
high diagnostic accuracy, and are routinely used as an
AD diagnostics tool in some countries, their further ac-
ceptance is hampered by problems with comparability of
the results obtained in different centers or even in one
center but with different analytical platforms. This issue
has already been addressed, to some extent, by efforts to
standardize procedures for sample collection, measure-
ments protocols and assay calibrators, but global accept-
ance of these novel approaches will certainly take time
[2–5]. Moreover, as the AD CSF biomarkers are progres-
sively used in daily clinical practice, interpretation of the
results needs expertise and caution and the question re-
mains how to interpret the information given by the
biomarkers, that is often heterogeneous, with not all
biomarkers falling into clear-cut normal/abnormal
categories.
In order to harmonize the clinical interpretation of the
CSF biomarker profiles, the Erlangen Score (ES) inter-
pretation algorithm was first proposed [6], followed by
other approaches, including logistic regression models
[7], classification scales based on the number of patho-
logic biomarkers, like the Paris–Lille–Montpellier (PLM)
scale [8, 9], or a nominal-scale A/T/N system [10]. In
contrast to other interpretation algorithms, the ES en-
ables ordering of the CSF patterns into five ordinal clas-
ses (0–4) with increasing degree of alterations. Analysis
of the two pathologies (amyloidosis and neurodegenera-
tion), as is done in the ES algorithm, can be seen from
the perspective of topologic analysis of a geometric ob-
ject; the concept of the dimension of a geometric object
(in our case, interpretation of two independent groups
of AD biomarkers) is the number of independent param-
eters (one for amyloid pathology and one for neurode-
generation) needed to pick out a unique point inside the
object. However, any point specified by two parameters
(amyloidosis and neurodegeneration) can instead be spe-
cified by one; in our case, the total score. Further, the ES
introduces, for the first time in the interpretation of CSF
AD biomarkers, the concept of border zone results. In a
previous study, the ES was shown to correctly classify
nondemented/mild cognitive impairment (MCI) subjects
at increased risk of developing dementia in two inde-
pendent, large-scale, multicenter cohorts (German Com-
petence Network Dementias and US-ADNI), irrespective
of the fact that they used entirely different sample hand-
ling protocols, disparate laboratory analytical platforms,
and uncorrelated center-specific reference ranges [11].
Continuing the validation of the ES algorithm, in the
current study we tested whether the ES is capable of ac-
curately predicting hazards of progression from the MCI
stage of AD to the dementia stage of the disease (Alzhei-




The population studied here derives from the Coimbra
cohort described elsewhere [12]. AD dementia patients
(ADD, n = 168) and MCI patients (n = 144) were re-
cruited at the Dementia Clinic, Neurology Department
of Coimbra University Hospital, according to the base-
line and follow-up protocol already published [12]. Pa-
tients were enrolled in a systematic way and had
biannual clinical observation and annual neuropsycho-
logical and functional evaluations. All patients under-
went a thorough biochemical, neurological, and imaging
(CT or MRI and SPECT) evaluation. At baseline, a neur-
ologist completed a medical history with the patient and
the caregiver, and conducted a general physical, neuro-
logical, and psychiatric examination as well as a compre-
hensive diagnostic battery protocol, including: cognitive
instruments such as the Mini Mental State Examination
(MMSE) [13] Portuguese version [14], the Montreal
Cognitive Assessment (MoCA) [15] Portuguese version
[16], the Alzheimer Disease Assessment Scale–Cognitive
(ADAS-Cog) [17, 18] Portuguese version [19], and a
comprehensive neuropsychological battery with norma-
tive data for the Portuguese population (Lisbon Battery
for Dementia Assessment (BLAD) [20]) exploring mem-
ory (Wechsler Memory Scale subtests) and other cogni-
tive domains (including language, praxis, executive
functions, and visuo-construtive tests); and standard sta-
ging scales which provide objective information about
subject performance in various domains, including the
Clinical Dementia Rating scale (CDR) [21] for global sta-
ging, the Disability Assessment for Dementia (DAD) [22,
23] for evaluation of functional status, and the Neuro-
psychiatric Inventory (NPI) [24, 25] to characterize the
psychopathological profile, including the presence of de-
pression. All of the available information (baseline cog-
nitive test, staging scales, clinical laboratory, and
imaging studies) was used to reach a consensus research
diagnosis. A similar approach was used for follow-up
evaluations annually. Neither CSF biomarkers nor PET
were taken into account in the diagnoses.
MCI patients included in this study were of the
amnestic type and the diagnosis was made in accordance
with the criteria defined by Petersen et al. [26] and more
recently the framework for MCI due to AD, proposed by
the NIA–AA criteria [27]. Petersen’s criteria were
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operationalized as follows: a subjective complaint of
memory decline (reported by the subject or an inform-
ant); an objective memory impairment (considered when
scores on standard Wechsler memory tests were > 1.5
SDs below age/education-adjusted norms) with or without
deficits in other cognitive domains; normal general cogni-
tion suggested by normal scores in the MMSE and MoCA
using the Portuguese cutoff scores [14, 28]; largely normal
daily life activities, evaluated with a functional scale
(DAD); and absence of dementia, indicated by a CDR rat-
ing of 0.5. All patients were in a stable condition, without
acute comorbidities. As exclusion criteria for enrolment,
we considered a significant underlying medical or neuro-
logical illness revealed by laboratory tests or imaging; a
relevant psychiatric disease, including major depression,
suggested in the medical interview and confirmed by the
GDS; and CT or MRI demonstration of significant vascu-
lar burden [29] (large cortico-subcortical infarct; extensive
subcortical white matter lesions superior to 25%; unilateral
or bilateral thalamic lacunes; lacunes in head of caudate
nucleus; more than two lacunes).
MCI cases were followed-up with this comprehensive
protocol until they developed dementia or until they had
been cognitively stable for at least 2 years, and were fur-
ther dichotomized into those who were cognitively stable
and those who developed ADD. No MCI patients who de-
veloped types of dementia other than ADD were included
in this study. Progression to ADD required fulfilling clin-
ical diagnostic criteria for probable AD (see later) and was
operationalized as follows: objective evidence, by cognitive
testing, of decline to dementia using the MMSE, MoCA,
and ADAS-Cog scores and qualitative evaluation (i.e., im-
pairment of memory plus another domain); and changes
in global CDR rating from 0.5 to 1 or more, confirming
the cognitive profile of dementia and loss of autonomy.
Dementia was diagnosed according to the 2011 NIA–
AA criteria [30]. These cases were classified as probable
ADD according to clinical and neuroimaging features.
We also included 66 neurological controls. Most of
these individuals suffered from acute or chronic head-
aches, and a lumbar puncture (LP) was performed as
part of their routine diagnostic evaluation in order to ex-
clude bleeding or inflammation; in some cases, this pro-
cedure was considered in the investigation of a
peripheral polyneuropathy. In both cases, the CSF cyto-
chemical evaluation was normal and a major CNS dis-
ease was excluded. In their brief cognitive evaluation,
the controls showed no subjective cognitive complaints,
were independent in their instrumental daily life activ-
ities, and most of them were still professionally active.
Laboratory determinations
CSF samples were collected from the subjects as part of
their routine clinical diagnosis investigation. Preanalytical
and analytical procedures were done in accordance with
previously proposed protocols [31]. Briefly, CSF samples
were collected in sterile polypropylene tubes, immediately
centrifuged at 1800 × g for 10min at 4 °C, aliquoted into
polypropylene tubes, and stored at –80 °C until analysis.
CSF Aβ1–42, Aβ1–40, Tau, and pTau181 were measured
in the laboratory in Coimbra, in duplicate, by commer-
cially available sandwich ELISAs (Innotest; Innogenetics/
Fujirebio, Ghent, Belgium), as previously described [12].
In our hands, the mean intra-assay coefficients of vari-
ation (CVs) of these methods were 4.2% for Aβ1–42, 3.8%
for Aβ1–40, 4.5% for Tau, and 4.2% for pTau181, and
inter-assay CVs were 8.1% for Aβ1–42, 13.2% for Aβ1–40,
7.0% for Tau, and 7.2% for pTau181. In addition, external
quality control of the measurements was performed under
the quality control scheme of the Alzheimer’s Association
Quality Control Program for CSF Biomarkers [32].
The reference values used in our laboratory, and ap-
plied in this paper, are 580 pg/ml for Aβ1–42, 0.068 for
Aβ42/Aβ40, 250 pg/ml for Tau, and 37 pg/ml for
pTau181.
Blood samples were also collected from MCI and AD
patients for apolipoprotein E (APOE) genotyping. DNA
was isolated from whole EDTA-blood using a commer-
cial kit (Roche Diagnostics GmbH, Manheim, Germany),
as described by the manufacturer. The analysis of the
two polymorphisms at codons 112 and 158 of the APOE
gene (rs429358 and rs7412) was performed by
PCR-RFLP assay, as previously described [33].
Erlangen Score
The ES was calculated according to the algorithm de-
scribed elsewhere, and with border zone results defined as
a pathologic result within 10% of the reference value (i.e.,
10% decrease in Aβ1–42 and/or Aβ42/40, or 10% increase
Tau and/or pTau181) [6, 11]. Briefly, a CSF result with all
biomarkers normal is scored 0 points, and reported as “no
neurochemical evidence for AD”; a pattern with border
zone alterations in one biomarkers group (either Aβ or
Tau/pTau, but not both) results in a score of 1, and is re-
ported as “neurochemically improbable AD”; a CSF result
with evident alterations in either Aβ metabolism (de-
creased Aβ1–42 concentration or Aβ1–42/Aβ1–40 ratio)
or tau metabolism (increased concentrations of Tau and/
or pTau181), but not both, is scored 2 points; and the
same score of 2 points is given in the case of border zone
alterations in the CSF biomarkers of both groups. A result
with evident alterations in one biomarkers' group (either
Aβ or Tau) accompanied by border zone alterations in the
other group is scored 3 points; these two cases (with the
ES = 2 or 3) are reported as “neurochemically possible
AD”. Finally, evident alterations in both Aβ and Tau
groups result in 4 points, and are reported as “neuro-
chemically probable AD”. Additional file 1: Table S3
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presents the ES in a form of a set of the if/then “com-
mands”, easily implementable into laboratory software.
Statistical analyses
If not stated otherwise, results of the continuous vari-
ables are presented as medians and interquartile ranges.
Wherever appropriate, 95% confidence intervals (CIs)
are reported. Distributions of categorical variables are
presented as numbers or percentages per group. Differ-
ences between groups in continuous variables were
tested with a t test, and differences in distribution of cat-
egorical variables classified by an ordinal variable with a
Kruskal–Wallis rank test adjusting for ties, followed by
Dunn’s pairwise comparison with Bonferroni correction.
Survival analyses were performed and visualized first
with unadjusted Kaplan–Meier (KM) estimators, accom-
panied by Nelson–Aalen (NA) cumulative hazard esti-
mators. The differences across the ES categories were
tested with a log-rank test, including testing trend, and
with a Wilcoxon test. Next, the hazard ratios (HRs) of
progression to dementia were modeled by Cox regres-
sion, with the explanatory variables as stated in the
corresponding models (M0–M3). The proportionality
assumption was checked by the Schoenfeld residuals test
under the null hypothesis that the HRs are time con-
stant, and by visual inspection of the KM and NA
curves. Since the hazard proportionality assumption was
violated, the Extended Cox Model (ECM) was preferred
over the Cox proportional hazard (CPH) model, with the
ES category “neurochemically possible AD” included in
the models as a time-varying variable interacting with
the Heaviside function splitting the follow-up time into
“less or equal than 3 years” and “more than 3 years”.
Logistic regression was used to model the conditional
probability of progression to ADD at 3-year and 5-year
follow-up. Linear regression was used to model concentra-
tions of the CSF biomarkers in MCI subjects who pro-
gressed to ADD within 3 years (fast progressors) compared
to those who did not (slow progressors), adjusted for age,
gender, and the MMSE score. To test whether biomarker
patterns in fast and slow progressors differ by ES categor-
ies, interaction terms of ES categories with the Heaviside
function, defining fast and slow progression, were included
in these models. Linear marginal (population-averaged)
predictors, adjusted for the covariates kept at their means,
were then post-estimated from the models and are pre-
sented with their 95% CI. p < 0.05 was considered statisti-
cally significant. All analyses were done with Stata 14.2
(StataCorp, College Station, TX, USA).
Results
Demographics of groups and results of CSF biomarkers
The demographics of the groups and the results of the CSF
biomarkers are presented in Table 1; the detailed statistical
comparisons of the four groups are published elsewhere
[12]. Briefly, MCI-Stable patients (i.e., those who did not
progress to dementia during the study) were significantly
younger, had borderline significantly higher MMSE scores,
and had significantly higher CSF Aβ1–42 and Aβ42/40 as
well as significantly lower CSF Tau and pTau181 com-
pared to the MCI-AD patients (i.e., those who progressed
to ADD). The MCI-AD group was significantly enriched
in APOE ε4 carriers. There were no significant differences
in the CSF Aβ1–40 concentrations and in the gender dis-
tribution between the two groups.
Distribution of Erlangen Score categories across
diagnostic groups
The distribution of the five ES categories (0–4) across
the four diagnostic groups is presented in Additional file
1: Table S1. Due to expectedly low numbers of cases in
the categories with 1 and 3 points, and in line with the
operating procedure of reporting the ES to physicians in
the daily routine, we combined the categories with 0 or
1 points as “neurochemically improbable AD”, and the
categories with 2 or 3 points as “neurochemically pos-
sible AD”. The distribution of these three categories
(neurochemically improbable AD, neurochemically pos-
sible AD, and neurochemically probable AD) across the
four diagnostic groups (Controls, MCI-Stable, MCI-AD,
and ADD) is presented in Table 2. In both categorization
approaches (i.e., into five and into three ES categories),
highly significant differences were observed in the ES
distributions across the groups (Kruskal–Wallis χ2(df = 3)
= 151.4, p < 0.001), confirmed by contrasts between each
pair of the groups (p < 0.005 in five group-to-group com-
parisons), except between the ADD and the MCI-AD
groups (p = 1.0). Within the subgroup of control patients
who tested positive (ES ≥ 2; n = 29), one was then lost for
follow-up, one is now classified as vascular dementia, and
27 remain without cognitive impairment. Within AD pa-
tients with ES ≤ 2 (n = 35), six dropped out, two changed
their classification to non-AD pathology (one vascular de-
mentia and one hippocampal sclerosis), and 27 remain
classified as AD.
Hazard ratios of progression from MCI to AD dementia
estimated by Extended Cox Models
Figure 1 presents the unadjusted KM survival curves in
the three ES categories (neurochemically normal or im-
probable AD, neurochemically possible AD, and neuro-
chemically probable AD). In addition, Additional file 1:
Figure S1 presents the Nelson–Aalen estimators of the
cumulative hazard functions of the three ES categories.
Table 3 presents the HR estimates of the ECM, modeling
the hazards of progression from MCI to ADD as the
functions of the Erlangen Score (the first model, M0),
plus the demographic covariates (age and gender, M1),
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supplemented further with the APOE genotype (M2),
and finally completed with the cognitive status (MMSE
score, M3). KM estimates turned out highly significantly
different from one another (p < 0.001), with the value of
the χ2 statistics from the log-rank test considerably lar-
ger than that from the Wilcoxon test (34.8 and 22.2, re-
spectively). The latter finding speaks for smaller
differences across the KM estimators at the earlier ob-
servation time and larger differences at the later obser-
vation time. This is consistent with overlapping of the
neurochemically possible and neurochemically probable
Nelson–Aalen cumulative hazard estimators in the first
3 years of observation, which then split apart leading to
the possible AD NA curve parallel to the improbable
AD NA curve, and considerably different from the prob-
able AD NA curve.
The trend across the three ES KM survival functions
turned out highly significant (χ2(df = 1) = 33.11, p < 0.001).
Finally, the null hypothesis of the proportionality of
the hazards was formally tested and rejected (p = 0.016).
As a consequence, the ECM was preferred over the CPH
model, with the estimated HR of the neurochemically
possible AD category split into HR at the early (before 3
years) and at the late (after 3 years) follow-up time. Add-
itional file 1: Table S2 presents the results of the CPH
model, for sake of comparison with other studies.
Irrespective of all covariates (age, gender, APOE geno-
type, and MMSE score), patients with neurochemically
possible AD (ES = 2 or 3) had about 6–8 times higher
hazards to progress to ADD compared to the patients
with neurochemically improbable AD (ES = 0 or 1) in
the first 3 years, and then their hazards became compar-
able to those of the neurochemically improbable group.
Patients with neurochemically probable AD (ES = 4) had
hazards of progression to dementia 8–12 times higher
compared to the neurochemically improbable AD group.
Conditional on the covariates, the neurochemically
probable AD group had hazards comparable to the neu-
rochemically possible AD group in the first 3 follow-up
years (M3: HR = 1.4, p = 0.31), which then became sig-
nificantly higher (HR = 8.8, p < 0.005).
None of the other covariates tested in this study had
significant HR estimates when adjusted for the Erlangen
Score and/or other covariates. Of some relevance, per-
haps, is that the MMSE score and the APOE genotype
showed insignificant tendencies toward HR estimates
different from 1, with each point increase of the MMSE
score decreasing the hazard of progression by about 5–
6% (M3: p = 0.16), and with the APOE ε4 genotype
increasing the hazard of progression by about 50% (M3:
p = 0.14), adjusted for other covariates.
Probabilities of progression from MCI to AD dementia at
3 and 5 years after initial diagnoses
Table 4 presents two logistic regression models, estimat-
ing the probability to develop AD dementia within 3 and
Table 1 Demographic data and results of cerebrospinal fluid biomarkers
Control group (n = 66) MCI-Stable group (n = 74) MCI-AD group (n = 70) ADD group (n = 168) p valuea
Age (years) 57.5 (51–68) 65 (59–73) 71 (68–76) 68.5 (62–75) < 0.001
Female gender (%) 59 66 63 67 0.73
APOE ε4 carriers (%) NA 28 60 46 < 0.001
MMSE NA 28 (25–29) 25 (23–28) 18 (14–21) 0.049
Maximum follow-up (years) NA 16.0 10.0 NA NA
Aβ1–42 (pg/ml) 852.9 (637.7–1041.1) 780.0 (572.2–949.0) 459.6 (352.3–603.8) 388.6 (308.2–532.7) < 0.001
Aβ1–40 (pg/ml) 8833 (6537–11,471) 10,659 (7672–13,443) 10,379 (8088–12,265) 8410 (6803–11,489) 0.53
Aβ42/40 0.100 (0.074–0.127) 0.079 (0.044–0.108) 0.046 (0.035–0.059) 0.046 (0.034–0.065) < 0.001
Tau (pg/ml) 178.3 (141.7–221.6) 215.5 (139.6–335.5) 448.0 (302.9–638.8) 459.7 (289.3–702.8) < 0.001
pTau181 (pg/ml) 29.6 (22.5–37.0) 33.9 (24.0–46.7) 59.0 (38.3–75.0) 55.2 (39.1–79.8) < 0.001
Continuous variables presented as median (interquartile range); proportions presented as percentage in a given group
Aβ amyloid beta, AD Alzheimer’s disease, ADD Alzheimer’s disease dementia, APOE apolipoprotein E, MCI mild cognitive impairment, MMSE Mini Mental State
Examination, NA not applicable
aContrasting MCI-Stable and MCI-AD groups. Continuous variables tested with two-tailed t test; proportions tested with Kruskal–Wallis test
Table 2 Distribution of Erlangen Score neurochemical
categories across the four diagnostic groups
Diagnostic category Erlangen Score neurochemical category
Improbable AD Possible AD Probable AD
Control group (n = 66)a 37 (56.1%) 28 (42.4%) 1 (1.5%)
MCI-Stable group (n = 74)a 29 (39.2%) 25 (33.8%) 20 (27.0%)
MCI-AD group (n = 70)b 3 (4.3%) 16 (22.9%) 51 (72.8%)
ADD group (n = 168)b 9 (5.4%) 35 (20.8%) 124 (73.8%)
Presented as number (percentage of the total number) in a given
diagnostic group
AD Alzheimer’s disease, ADD Alzheimer’s disease dementia, MCI mild
cognitive impairment
aDistribution significantly different (p < 0.005) from distributions in all three
other categories
bDistribution significantly different (p < 0.005) from distributions in Control and
MCI-Stable group, but not in ADD group (p = 1.0)
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Fig. 1 Kaplan–Meier survival curves of the three Erlangen Score (ES) categories. Note overlapping “possible” and “probable” curves in first 3 years,
which then split apart with “possible” curve parallel to “improbable” curve. Table shows number of patients at beginning of each 2-year time
interval, and numbers of patients having progressed to ADD or having been lost (censored) during each interval
Table 3 Extended Cox Models, estimating hazards of progression to AD dementia as functions of the covariates and with
neurochemically possible AD category as a time-dependent variable, split into “before 3 years follow-up” and “after 3 years follow-up”
Covariate M0 (n = 144) M1 (n = 144) M2 (n = 139) M3 (n = 131)
Erlangen Score (reference category: Improbable AD)
Possible AD
Before 3-year follow-up 7.67 (2.08–28.27)* 7.75 (2.05–29.27)* 7.43 (1.95–28.37)* 5.68 (1.47–21.97)*
After 3-year follow-up 1.04 (0.20–5.47) 1.04 (0.20–5.50) 0.94 (0.18–4.99) 0.92 (0.17–4.91)
Probable AD 12.0 (3.67–39.46)* 12.3 (3.60–42.19)* 10.8 (3.09–37.38)* 8.09 (2.29–28.56)*
Age (years) – 1.00 (0.97–1.03) 1.00 (0.97–1.03) 1.00 (0.96–1.03)
Female gender – 1.10 (0.68–1.81) 1.07 (0.66–1.75) 1.05 (0.63–1.75)
APOE ε4 presence – – 1.42 (0.86–2.36) 1.48 (0.88–2.48)
MMSE – – – 0.95 (0.87–1.02)
Log likelihood − 284.0 − 283.9 − 280.6 − 264.5
Compare with the corresponding Kaplan–Meier curve (Fig. 1). Hazard ratios compared to reference category (neurochemically improbable, i.e. Erlangen Score = 0
or 1) presented together with the corresponding 95% confidence intervals
AD Alzheimer’s disease, APOE apolipoprotein E, M0 model with ES as the only covariate, M1 M0 supplemented with age and gender, M2 M1 supplemented with
APOE genotype, M3 M2 supplemented with MMSE score, MMSE Mini Mental State Examination
*Statistical significance at p < 0.05 level, compared to the reference category
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5 years of the follow-up, respectively. Adjusted for age,
gender, and the MMSE score, patients with neurochemi-
cally possible AD had about 9 and 4 times larger odds to
become demented within 3 and 5 years, respectively,
compared to the reference category, although these esti-
mates are statistically weak (borderline significant (p =
0.048) after 3 years, and insignificant (p = 0.12) after 5
years). In contrast, patients with neurochemically prob-
able AD had odds about 16 times larger at both
follow-up time points, and these estimates were highly
significant (p < 0.01 in both models). Adjusted for other
covariates, the odds ratios of neither age nor gender nor
MMSE score were significant.
CSF biomarker pattern in subjects progressing from MCI
to ADD within shorter time (faster progressors)
Following the observation of the time-dependent hazard
ratio to progress from MCI to ADD in the neurochemi-
cally possible AD category, we stratified MCI patients
into a subgroup who progressed into ADD within 3
years (fast progressors, n = 47) and a subgroup of pa-
tients whose dementia-free follow-up time was longer
than 3 years (slow progressors, n = 74). We observed a
highly significant difference of the ES distributions be-
tween these two groups (χ2(df = 1) = 12.47, p < 0.001). In
the neurochemically possible AD category, adjusted for
age, gender, and MMSE score, faster progressors (n = 13)
had, in comparison to slower progressors (n = 24), sig-
nificantly lower CSF concentrations of Aβ1–42 [443
(95% CI 301–585) vs 830 (95% CI 726–932) pg/ml, p <
0.001] and Aβ1–40 [8338 (95% CI 6342–10,334) vs
11,347 (95% CI 9897–12,797) pg/ml, p = 0.018], and sig-
nificantly lower Aβ42/40 ratio [0.054 (95% CI 0.040–
0.069) vs 0.075 (95% CI 0.065–0.086), p = 0.023], but
comparable concentrations of Tau [291 (95% CI 157–
425) vs 275 (95% CI 177–372) pg/ml, p = 0.85] and
pTau181 [39.1 (95% CI 25.9–52.2) vs 38.3 (95% CI 28.8–
47.9) pg/ml, p = 0.93]. We did not observe differences in
the CSF biomarkers or other variables between fast and
slow progressors in either the neurochemically improb-
able or the neurochemically probable group. Adjusted
for other variables, neither age nor gender nor MMSE
score differed significantly between fast and slow
progressors.
Discussion
In this study, we confirmed our working hypothesis that
the hazard of progression from the MCI stage to the de-
mentia stage in AD strongly depends on the CSF bio-
marker pattern interpreted according to the Erlangen
Score, and hence that the ES is a helpful tool as a pre-
dictor of dementia development in MCI subjects.
Expectedly, the distribution of the patients with differ-
ent ES categories across the four diagnostic groups ana-
lyzed in this study showed statistically significantly
higher proportions of patients with the highest ES out-
come (ES = 4) in the ADD and the MCI-AD groups,
compared to the neurologic controls and the stable MCI
groups, which in turn showed a higher proportion of
subjects with the lowest ES (0 or 1). The finding of es-
sentially the same proportions of the ES categories in
ADD and MCI-AD is fully in line with the currently
most widely accepted model of the disease, which states
that MCI-AD is a predementia stage in the continuity of
ongoing AD pathology, and that the CSF biomarkers are
capable of diagnosing the disease much before the devel-
opment of the clinically observable dementia [34]. In
our study, only 5% (12/238) of patients with AD were
misclassified as “neurochemically improbable AD”, and
only one of 66 neurologic controls was misclassified as
“neurochemically probable AD”, which results in 95%
sensitivity and 98.5% specificity. Intermediate distribu-
tion of the ES categories observed in the MCI-Stable
group could be explained by the relatively short observa-
tion time; one cannot exclude that some of the MCI
subjects so far stable will eventually have developed de-
mentia in the future. Intermediate scores (ES = 2 or 3)
observed in the neurologic controls as well as in MCI
patients are attributable to imperfect accuracy of the AD
biomarkers, rather than the weakness of the ES algo-
rithm. Categorization of a patient within the “neuro-
chemically possible AD” group should be seen, from that
perspective, as a laboratory-driven recommendation to
closely look at the results of other diagnostic modalities
and to follow-up the patient to eventually disclose/con-
firm AD.
Empirical survival ES KM curves show highly signifi-
cant differences, with a similarly highly significant trend.
MCI patients classified as “neurochemically probable
AD” had 8–12 times higher hazards to develop dementia
Table 4 Logistic regression, modeling probability to progress to
AD dementia within 3 and 5 years, respectively, as functions of
age, female gender, and initial MMSE score
Covariate Progression within 3 years
(n = 116)
Progression within
5 years (n = 96)
Erlangen Score (reference category: Improbable AD)
Possible AD 8.93 (1.02–78.04)* 3.90 (0.71–21.32)
Probable AD 16.32 (1.96–136.2)* 16.77 (2.95–95.40)*
Age (years) 1.00 (0.95–1.06) 1.01 (0.95–1.08)
Female gender 1.24 (0.52–2.92) 0.94 (0.34–2.59)
MMSE 0.90 (0.80–1.02) 0.91 (0.77–1.08)
Log likelihood −66.6 −50.8
Odds ratios (95% confidence intervals) compared to the reference category
(AD neurochemically improbable, i.e. Erlangen Score = 0 or 1)
AD Alzheimer’s disease, MMSE Mini Mental State Examination, n number of
patients in a given model
*Statistical significance at p < 0.05 level, compared to the reference category
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than those classified as “neurochemically improbable
AD”, adjusted for age, gender, MMSE score, and APOE
genotype, and these hazard ratios were apparently time
independent. On the other hand, the hazards associated
with the demographic, cognitive, and genetic con-
founders were fully explained by the ES. Of particular
relevance is that the hazards aligned with the two mostly
accepted AD risk factors, age and APOE ε4 presence, are
entirely explained by the ES categorization. Interestingly,
in this study the hazard ratios in the “neurochemically
possible” group turned out time dependent, showing sig-
nificantly higher values in the first 3 years of follow-up,
and then getting lower and comparable to the hazards in
the “neurochemically improbable” group. This means
that the probability to develop dementia in this group
continuously increases but at a decreased rate after ca.
2–3 years. A large proportion (ca. 30%) of the MCI cases
with “possible” scores developed dementia in the first 3
years of follow-up. This could be explained considering
that: hazard ratios are relative metrics, normalizing the
hazard in one category to the hazard in a reference cat-
egory (“neurochemically improbable AD” in this case),
the latter also showing some instable cases progressing
to dementia (ca. 15% after the 4th follow-up year), even
if their CSF results at the beginning of the study were
normal; and the hazards, as they are considered in this
study, are functions of the CSF results obtained once at
the beginning of the observation and implicitly assumed
to be constant over the whole follow-up time, which cer-
tainly does not need to be true. For example, it could
happen that in a relatively short time after the LP
(within 2–3 years), alterations in other biomarkers would
append in addition to those already observed, changing
a patient’s ES-based categorization from “possible” to
“probable”. Interestingly, in this ES category, but not in
the two others, significant differences of the CSF pat-
terns between the fast and the slow progressors were ob-
served, with amyloid biomarkers significantly lower in
the former group. This observation stays in accordance
with the hypothesis that an altered amyloid pathway
triggers neurodegeneration, which then stimulates cogni-
tive decline [35]; in such a scenario, biomarkers of neu-
rodegeneration could have perhaps been observed in the
CSF if the LP had been performed later in the course of
the disease. In any case, it is plausible to conclude that
the predictive value of the intermediate ES results (“neu-
rochemically possible AD”) is most obvious within about
3 years following the CSF analysis, in contrast to clearly
time-independent interpretation of either “improbable
AD” or “probable AD”. Further, altered amyloid bio-
markers, in this category, are particularly relevant as
predictors of the MCI-ADD progression. This is also
reflected by the results of the two logistic regression
models, showing much higher odds ratios of having
developed dementia after 3 years (8.9) compared to the
odds ratios after 5 years (3.9) in the “possible” group,
with consistently high odds ratios in the “probable”
group (~ 16).
Compared to other classification and interpretation
systems, the Erlangen Score shows clear advantages. It
allows more precise stratification of patients into five
categories with increasing degree of the CSF pathology,
in contrast to the dichotomous approach (CSF normal/
pathologic) applied by Hansson et al. [36]. Compared to
regression-based approaches [7], the ES is much simpler;
in everyday laboratory routine it does not need
computer-based support at all—scoring of a CSF result
consisting of four biomarkers takes less than 5 seconds
for a moderately experienced person. Compared to the
A/T/N classification [10], the ES stratifies subjects into
classes on an ordinal scale, and not into purely nominal
categories, which enables at least semi-quantitative cor-
relation of the CSF findings with other metrics, like pro-
gression hazards, odds ratios, or survival-to-dementia
time. Further, as an ordinal-scale classification system,
the ES is able to take border-zone laboratory results into
consideration, easily incorporating them into the inter-
preting algorithm. In contract, A/T/N is a purely nom-
inal approach, which prevents existence of any
“borderline” categories. Finally, compared to the PLM
approach, which is based on the number of pathologic
CSF biomarkers [9], the ES is more flexible, enabling in-
clusion of further potential biomarkers (as long as they
reflect amyloid pathology or neurodegeneration at least
on an ordinal scale) without necessity to redefine the
ranges (i.e., the number of categories). Irrespective of the
number of biomarkers considered, the ES will always
classify the CSF patterns into five ordinal categories. As
a matter of fact, in a previously published study the ES
was successfully validated even when derived from three,
instead of four, biomarkers available in the US-ADNI co-
hort, albeit with clearly less conclusive results compared
to the validation based on four biomarkers available in
the German CND cohort [11]. Flexibility of the ES ex-
tends its potential application beyond the CSF bio-
markers; actually, results of every diagnostic modality,
which analyzes amyloid pathology or neurodegeneration
on a quantitative or at least semi-quantitative scale (like,
for example, Aβ or Tau positron emission tomography),
could be used to calculate the Erlangen Score. On the
other hand, in comparison with the A/T/N classification,
the ES is less informative, as the same score (in the cat-
egories 1, 2, and 3) can result from different combina-
tions of biomarkers, and therefore have a different
biological meaning. For instance, according to the ES,
both patients with abnormal amyloid and normal neuro-
degeneration markers or with normal amyloid and ab-
normal neurodegeneration markers would score 2, and
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would therefore be given a similar interpretation in
terms of CSF biomarker profile, whereas the A/T/N
classification would attribute a completely different bio-
logical significance to these profiles. This could be of
relevance when using biomarker profiles for patient re-
cruitment in clinical trials, where specific pathological
pathways are being targeted and therefore detailed infor-
mation on which specific markers are altered is needed.
To overcome this limitation, we postulate amending a
numerical score with a graphic representation of the bio-
markers’ pattern in the form of a table with the rows
and the columns representing partial scorings for amyl-
oid and neurodegezneration biomarkers, respectively,
and with the total score in the table’s body (see Fig. 1 in
[1]). Finally, it needs to be stressed, that as soon as la-
boratory (or method)-specific reference values for the
biomarkers are established, the interpretational approach
offered by the ES algorithm is independent of the center,
laboratory platform, preanalytical sample handling pro-
cedures, and so forth. This characteristic might be seen
as one of the most important advantages of the ES, since
discrepancies in laboratory and method-specific cutoff
values are one of the major problems hampering further
acceptance of the CSF biomarkers as a routine AD diag-
nostic tool. This is clearly seen from the comparison of
the interpretations in two completely independent co-
horts, analyzed in two distinct laboratories, reported
previously [11].
Our current results reconfirm the conclusions of
the previously published report [11], even if the lower
number of borderline results (particularly those with
ES = 3) in the current study precludes a more detailed
analysis of the relative hazards of this particular cat-
egory. On the other hand, in contrast to the ADNI
cohort, which has only three AD biomarkers available,
in the current study we were able to evaluate the ES
based on its original four-biomarker algorithm (i.e.,
including the Aβ42/40 ratio in addition to Aβ1–42,
Tau, and pTau181). We believe that this is the reason
for somehow higher hazard ratios in this study, par-
ticularly in the neurochemically probable AD category,
which could be interpreted as a more clear separation
of the categories achieved due to inclusion of the
Aβ42/40 ratio, a biomarker well known to improve the
accuracy of the AD diagnostics [12, 37–39]. On the
other hand, in the current study the confidence inter-
vals of the hazard ratios are broader, obviously as a
consequence of the smaller number of the cases. Taken
together, the same conclusions are obtained in both
studies (US-ADNI and the current one) in spite of the
fact that they have different settings (multicenter
versus monocenter), they apply entirely different
sample collection and handling protocols, they meas-
ure biomarkers with two different analytical methods
(multiplexing and ELISA, respectively), and of course
they use completely different sets of cutoff values.
This study is not without limitations, and perhaps the
most serious is the low number of subjects with border-
line biomarker concentrations, decreasing the sizes of
the categories with ES = 1 or ES = 3. On the other hand,
however, by definition the number of the borderline re-
sults should be low compared to the clear-cut results
(ER = 0 or 2 or 4). Also, as seen in the tabulated part of
Fig. 1, there is natural dropout of patients during the ob-
servation time, which limits the power of the conclu-
sions that can be drawn beyond 5 years. Further, it is not
the scope of this study to modify the current version of
the Erlangen Score algorithm in such a way that it would
apply different scoring weights to the biomarkers con-
sidered; for example, we are currently working on such a
modification that would take into consideration that
phosphorylated Tau seems to be a more specific AD bio-
marker than total Tau and that Aβ42/40 is obviously
more accurate AD biomarker than Aβ1-42.
Conclusions
Our results reconfirm and extend the conclusions of the
previously published report that the Erlangen Score is a
useful tool facilitating interpretation of a complex pat-
tern of the CSF AD biomarkers; particularly, the Er-
langen Score helps to understand CSF patterns in MCI
patients progressing to AD dementia.
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